礼邦医药-B(09637.HK):AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理

智通财经
Aug 07
【礼邦医药-B(09637.HK):AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理】智通财经APP讯,礼邦医药-B(09637.HK)发布公告,公司管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请,今日获中国国家药品监督管理局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验 RESPOND-1的结果及其他累积临床资料。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10